Amgen Inc.’s metastatic colorectal cancer drug Vectibix won approval for a label expansion from the U.S. Food and Drug Administration, the company announced Thursday.
Apollo Medical Holdings Inc. reported widening losses despite higher revenue in its most recent fiscal year.
MannKind Corp. on Thursday announced it has agreed to extend the due date of a $10 million loan owed to Deerfield Management Co. from July 2017 to October 2017.
MannKind Corporation on Wednesday announced that it has requested a final loan disbursement of $30.1 million from the Mann Group.
Amgen Inc. announced Monday that the U.S. Food and Drug Administration has accepted an application to expand on Xgeva’s indicated uses.
Simulation Plus Inc. released preliminary revenues for the third quarter of its fiscal year, which ended May 31.
SetPoint Medical today announced they have appointed Dr. David Chernoff as chief medical officer.
Michael Castagna has a big job in front of him. Last month he was appointed chief executive of MannKind Corp., the Valencia biotech company founded by late billionaire Alfred Mann.
MannKind Corp. has hired a consulting firm to find strategic and financial partners for development of its Technosphere platform, the company announced Monday.
The 2017 Amgen Tour of California is rolling through Santa Clarita Wednesday as the city is the finish line for the fourth day of the men’s weeklong bicycle race.
Shares of MannKind Corp. gained 15.6 percent Tuesday as the company prepares for its annual shareholder meeting amid takeover rumors.
Three medical office buildings on or near Valley hospital campuses have sold as part of an 11-property portfolio for $150 million, or $253 square feet.
Avita Medical Ltd., a Valencia company that makes regenerative treatments for wounds and skin defects, has filed a petition against a patent owned by competitor New York-based Renovacare Sciences Corp.
The U.S. Securities and Exchange Commission has accused 27 individuals and businesses of stock fraud, according to the Tampa Bay Business Journal, including former ImmunoCellular Therapeutics Ltd. chief executive Manish Singh.
Shares in MannKind Inc. zoomed up 43 percent Wednesday, but after the market closed the company reported that it seriously missed Wall Street expectations for earnings and revenue in the first quarter.